Extended use of brentuximab vedotin before autologous stem‐cell transplantation would benefit refractory systemic anaplastic large‐cell lymphoma

The optimal number of brentuximab vedotin cycles in the treatment of systemic anaplastic large‐cell lymphoma (sALCL) prior to autologous stem‐cell transplantation (ASCT) is unknown. This case illustrates the possible benefit of prolonged brentuximab vedotin before ASCT in sALCL and may help clinical...

Descripción completa

Detalles Bibliográficos
Autor principal: Koh, Youngil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930222/
https://www.ncbi.nlm.nih.gov/pubmed/29744059
http://dx.doi.org/10.1002/ccr3.1461
Descripción
Sumario:The optimal number of brentuximab vedotin cycles in the treatment of systemic anaplastic large‐cell lymphoma (sALCL) prior to autologous stem‐cell transplantation (ASCT) is unknown. This case illustrates the possible benefit of prolonged brentuximab vedotin before ASCT in sALCL and may help clinical decision‐making, especially in chemorefractory disease.

Ejemplares similares